Long-term remission of chronic-type adult T-cell leukemia/lymphoma associated with Graves’ disease treated with methimazole
- 1Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, Laboratory of Viral Oncology and Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan, IMSUT Clinical Flow Cytometry Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Abstract
Adult T-cell leukemia/lymphoma (ATL) is a rare T-cell malignancy, where the chronic type often progresses to an acute form in the presence of poor prognostic factors. We report a remarkable case of chronic-type ATL that achieved long-term hematologic and molecular remission following methimazole treatment for concomitant Graves’ disease. A 58-year-old woman was diagnosed with chronic-type ATL in 2022. Her disease showed gradual progression with elevated soluble interleukin-2 receptor (sIL-2R) levels and lactate dehydrogenase. In 2023, she developed Sjögren’s syndrome and Graves’ disease. Following the initiation of methimazole for hyperthyroidism, her abnormal lymphocyte counts and sIL-2R levels unexpectedly and rapidly decreased. She has maintained clinical stability for over two years without any cytotoxic chemotherapy. Multi-color flow cytometry confirmed the disappearance of the CD4+/CADM1+/CD7− ATL cell population in the peripheral blood. Furthermore, longitudinal genomic profiling using Target-seq revealed a significant reduction in the variant allele frequencies of major driver clones, including a PDCD1 frameshift mutation, and a shift from monoclonal expansion to a polyclonal HTLV-1 carrier state. This case provides the first clinical evidence of a potential anti-ATL effect of methimazole and underscores the importance of the endocrine-immune axis in HTLV-1–associated malignancies, warranting further investigation into antithyroid therapy as a novel treatment strategy for indolent ATL.
Related
- Leukemic fitness predicts treatment-free remission and guides adaptive therapy in chronic myeloid leukemia
- Composition of immune cells in peripheral blood of patients with leukemia in remission after stem cell transplantation (HSCT) with or without graft-versus-host disease (GvHD): a comparative analysis with healthy donors
- FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma
- Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations
- Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis
BibTeX
@article{fuji2026longterm,
title = {{Long-term remission of chronic-type adult T-cell leukemia/lymphoma associated with Graves’ disease treated with methimazole}},
author = {Shigeo Fuji and Kako Suzuki and Eri Watanabe and Kazumi Tsuchiya and Makoto Yamagishi},
journal = {Journal of Clinical and Experimental Hematopathology : JCEH},
year = {2026},
month = jul,
doi = {10.3960/jslrt.26028},
url = {https://doi.org/10.3960/jslrt.26028},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Long-term remission of chronic-type adult T-cell leukemia/lymphoma associated with Graves’ disease treated with methimazole
AU - Shigeo Fuji
AU - Kako Suzuki
AU - Eri Watanabe
AU - Kazumi Tsuchiya
AU - Makoto Yamagishi
PY - 2026
DA - 2026/07/30
JO - Journal of Clinical and Experimental Hematopathology : JCEH
DO - 10.3960/jslrt.26028
UR - https://doi.org/10.3960/jslrt.26028
AB - Adult T-cell leukemia/lymphoma (ATL) is a rare T-cell malignancy, where the chronic type often progresses to an acute form in the presence of poor prognostic factors. We report a remarkable case of chronic-type ATL that achieved long-term hematologic and molecular remission following methimazole treatment for concomitant Graves’ disease. A 58-year-old woman was diagnosed with chronic-type ATL in 2022. Her disease showed gradual progression with elevated soluble interleukin-2 receptor (sIL-2R) levels and lactate dehydrogenase. In 2023, she developed Sjögren’s syndrome and Graves’ disease. Following the initiation of methimazole for hyperthyroidism, her abnormal lymphocyte counts and sIL-2R levels unexpectedly and rapidly decreased. She has maintained clinical stability for over two years without any cytotoxic chemotherapy. Multi-color flow cytometry confirmed the disappearance of the CD4+/CADM1+/CD7− ATL cell population in the peripheral blood. Furthermore, longitudinal genomic profiling using Target-seq revealed a significant reduction in the variant allele frequencies of major driver clones, including a PDCD1 frameshift mutation, and a shift from monoclonal expansion to a polyclonal HTLV-1 carrier state. This case provides the first clinical evidence of a potential anti-ATL effect of methimazole and underscores the importance of the endocrine-immune axis in HTLV-1–associated malignancies, warranting further investigation into antithyroid therapy as a novel treatment strategy for indolent ATL.
SN - 1346-4280
SN - 1880-9952
ER -